Skip to main content

Paired Ends: Robert Schueren, William McKenzie

Premium

WaferGen has made changes to its board of directors following the firm's acquisition of IntegenX's next-gen sequencing library prep business. The company has reduced the size of its board of directors to seven from nine. In addition, Robert Schueren, IntegenX's CEO, will join WaferGen's board of directors. Prior to his role at IntegenX, Schueren was vice president and general manager of genomics at Agilent Technologies.

The board also appointed William McKenzie as a director, effective Dec. 30, 2013. Most recently, he served as president and general manager of molecular diagnostics at PerkinElmer.

Scott Davidson and Joseph Pesce, representatives of Great Point Partners, stepped down from the board, effective Dec. 30, 2013.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.